Replies to post #331474 on Anavex Life Sciences Corp (AVXL)

[$Money Bags$]

Not really. If it goes to market being the only real drug for it, it will need much less manpower to get over the finish line. If there was a sea of drugs for it, then for sure. Most people with family members of specific diseases do the legwork themselves. I know we sure have.

[Bourbon_on_my_cornflakes]

Contract manufacturer, contract distributor

80% to the bottom line for AVXL

If CM decides to go it alone for Rett syndrome
He will need a sales force to get it to medical offices
That’s a big job

He may have someone who can make
The drug
But getting it into he medical offices is a completely different job

I'm sure McKesson (pharma distributor) or someone else can handle it.

That is the ideal role for a distributor, handling a product with limited sales (orphan drug) such that it is not cost effective to build your own sales force.

[BAR123]

Not as big as you think for Rett or PDD. They know where the 10k patients are for Rett and they already have the manufacturing that can support it. Distribution will be easy for that number of patients. PDD should not be that bad as well. They will already have distributors set up for Rett and again manufacturing is a non issue. For these two indications maybe they need to hire an extra 10 people, if that. Alzheimer’s and Parkinson’s is where you will need a much larger presence.

[JWC3]

For RETT SYNDROME there are 10000 possible patients. That’s on average 200 patients per state. I think a very part time sales force is required. Not so critical and such a small number.

[powerwalker]

More FU* for the supernatural! Yuck!



ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!

[XenaLives]

Rett Syndrome advocates have been involved all along, there will be no problem "getting the word out":

The results of a US-based Phase 2 clinical trial evaluating the safety and efficacy of Anavex Life Sciences‘ investigational therapy ANAVEX®2-73 (blarcamesine) in Rett syndrome has been published, effectively establishing a human proof-of-concept that has resulted in a widespread celebration from within the rare disease advocacy community.



Rett syndrome is a rare neurodevelopmental disorder that almost exclusively affects girls. Estimated to occur in one of every 10,000 to 23,000 female births, the condition affects brain function and results in cognitive, emotional, sensory, motor, and autonomic problems. Classified as an autism spectrum disorder, Rett syndrome presents similarly to other rare autism spectrum conditions like Batten disease, Angelman syndrome, Fragile X disorders, and more.



The collective mindset of the Rare Advocacy Movement establishes “a win for one is a win for us all.” This sentiment couldn’t be more true in the case of today’s release of the results of the ANAVEX®2-73 (NCT03758924) trial in Rett syndrome. Here is why:

https://www.rareadvocacymovement.com/anavex-is-the-company-to-learn-from

[McMagyar]

What?
You think a sales rep will have to tell rett Symdrome doctors about a drug that works?

You have a lower opinion of Docs than
Is justified.
We will just need the shipping address

[Steady_T]

https://www.mckesson.com/Biopharma/Specialty-Drug-Distribution/

Anavex will sign up with one of the major drug distribution companies and that issue will be solved.

Word of mouth is the best and cheapest form of advertising. The Rett community is a well informed community and is desperate for something that can help their kids.

Anavex's external IR company will be able to inform the small population of Drs. that treat Rett syndrome. The question will be who informs the Drs. first, the parents calling the Dr. or Anavex IR. There will be publications in the specialty journals along with ads I would assume.